Liraglutide dosage: reported doses and schedule

A daily GLP-1 injection approved for weight management and type 2 diabetes.

Also called: Saxenda, Victoza, NN2211, Xultophy component.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

Typical reported dose: 0.6 mg once a day to start, up to 3 mg

  • Saxenda: weekly 0.6 mg steps: 0.6 mg once daily, then 1.2 mg once daily, then 1.8 mg once daily, then 2.4 mg once daily once daily, under the skin. Drug label. Studied in: Adults meeting the Saxenda weight-management indication. (source)
  • Victoza: 0.6, 1.2, then optional 1.8 mg: 0.6 mg once daily, then 1.2 mg once daily, then 1.8 mg once daily once daily, under the skin. Drug label. Studied in: Adults with type 2 diabetes. (source)
  • Xultophy: start at 10 dose units: Start 10 dose units daily; then adjust by 2 dose units once or twice weekly. once daily, under the skin. Drug label. Studied in: Adults with type 2 diabetes naive to basal insulin or a GLP-1 medicine. (source)
  • Xultophy: start at 16 dose units: Start 16 dose units daily; then adjust by 2 dose units once or twice weekly. once daily, under the skin. Drug label. Studied in: Adults with type 2 diabetes switching from basal insulin or a GLP-1 medicine. (source)
  • Early study: 0.045 mg daily: 0.045 mg once daily; fixed assigned dose. once daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
  • Early study: 0.225 mg daily: 0.225 mg once daily; fixed assigned dose. once daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Related to Liraglutide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.